Skip to content
10-Q

Quarterly Report

CYCLERION THERAPEUTICS, INC. CYCN

0001193125-26-219478

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 4.33M sh
Shares Diluted Q1 2026 · Mar 31, 2026 4.21M sh
Shares Diluted Q1 2026 · Mar 31, 2025 2.56M sh
Capex Q1 2026 · Mar 31, 2026 $66K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.18M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$968K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.82M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.24M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.79M
Stockholders Equity Q1 2026 · Dec 31, 2025 $9.09M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.71M
Current Liabilities Q1 2026 · Dec 31, 2025 $900K
Current Assets Q1 2026 · Mar 31, 2026 $3.09M
Current Assets Q1 2026 · Dec 31, 2025 $4.64M
Total Assets Q1 2026 · Mar 31, 2026 $8.51M
Total Assets Q1 2026 · Dec 31, 2025 $9.99M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.76
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.56
Eps Basic Q1 2026 · Mar 31, 2026 −$0.76
Eps Basic Q1 2026 · Mar 31, 2025 −$0.56
Sga Expense Q1 2026 · Mar 31, 2026 $2.48M
Sga Expense Q1 2026 · Mar 31, 2025 $1.5M
Rd Expense Q1 2026 · Mar 31, 2026 $730K
Rd Expense Q1 2026 · Mar 31, 2025 $36K
Net Income Q1 2026 · Mar 31, 2026 −$3.18M
Net Income Q1 2026 · Mar 31, 2025 −$1.43M
Operating Income Q1 2026 · Mar 31, 2026 −$3.21M
Operating Income Q1 2026 · Mar 31, 2025 −$1.46M